NRROS: A Potential Drug Target and Biomarker for Transforming Growth Factor尾 Activator LRRC33

Target Name: NRROS

NCBI ID: G375387

NRROS

NRROS: A Potential Drug Target and Biomarker for Transforming Growth Factor尾 Activator LRRC33

Abstract:

Transforming growth factor beta (TGF-β) plays a crucial role in cell growth, differentiation, and repair. The TGF-β signaling pathway has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. The discovery of NRROS, a novel TGF-β activator LRRC33-targeted RNA molecule, may provide new insights into the regulation of TGF-β signaling and serve as a potential drug target or biomarker.

Introduction:

TGF-β is a cytoplasmic protein that plays a vital role in cell growth, differentiation, and repair. The TGF-β signaling pathway is composed of multiple transcription factors, including SMAD, p16, and RASA2, which regulate the expression of target genes. TGF-β signaling is involved in the development and maintenance of tissues, including neural cord, liver, heart, and cancer.

NRROS, a novel TGF-β activator LRRC33-targeted RNA molecule, has been identified as a potential drug target or biomarker. NRROS is a 22-kDa RNA molecule that is expressed in various tissues, including liver, heart, and brain. NRROS has has been shown to promote the formation of the TGF-β complex, which is critical for the initiation of TGF-β signaling pathway.

Molecular Mechanisms:

The TGF-β signaling pathway is activated by various factors, including mechanical stress, chemotoxins, and growth factors. The LRRC33 protein is a key TGF-β activator that can activate the pathway. LRRC33 is a 33-kDa protein that contains a N- terminal base (-NHRGY), a conserved N-terminal domain, and a C-terminal transmembrane domain (-T/DMER).

LRRC33 has been shown to promote the formation of the TGF-β complex by interacting with the TGF-β receptor (TGFR) and the SMAD transcription factor. The TGF-β receptor is a transmembrane protein that is involved in the TGF-β signaling pathway . The TGF-β receptor is composed of an extracellular domain, a transmembrane domain, and an intracellular domain.

LRRC33 has been shown to interact with the TGF-β receptor by conserving its C-terminus. This interaction between LRRC33 and TGFR is critical for the formation of the TGF-β complex. LRRC33 has been shown to promote the recruitment of TGFR to the TGF -尾 complex, which is necessary for the subsequent activation of the pathway.

LRRC33 has also been shown to interact with the SMAD transcription factor, which is a critical transcription factor that regulates the expression of many target genes. The SMAD transcription factor is composed of a N-terminal domain, a T-domain, and a C- terminal domain.

Expressions and Functions:

LRRC33 is expressed in various tissues, including liver, heart, and brain. It has been shown to be involved in the regulation of cell growth, apoptosis, and inflammation. LRRC33 has been shown to promote the formation of the TGF-β complex, which is critical for the initiation of TGF-β signaling pathway.

LRRC33 has also been shown to be involved in the regulation of cell apoptosis. Studies have shown that LRRC33 can induce the apoptosis of cancer cells, which may have implications for the development of cancer therapies.

LRRC33 has also been shown to be involved in the regulation of inflammation. Studies have shown that LRRC33 can

Protein Name: Negative Regulator Of Reactive Oxygen Species

Functions: Key regulator of transforming growth factor beta-1 (TGFB1) specifically required for microglia function in the nervous system (By similarity). Required for activation of latent TGF-beta-1 in macrophages and microglia: associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGFB1, and regulates integrin-dependent activation of TGF-beta-1 (By similarity). TGF-beta-1 activation mediated by LRRC33/NRROS is highly localized: there is little spreading of TGF-beta-1 activated from one microglial cell to neighboring microglia, suggesting the existence of localized and selective activation of TGF-beta-1 by LRRC33/NRROS (By similarity). Indirectly plays a role in Toll-like receptor (TLR) signaling: ability to inhibit TLR-mediated NF-kappa-B activation and cytokine production is probably a consequence of its role in TGF-beta-1 signaling (PubMed:23545260)

The "NRROS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRROS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets